These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
742 related articles for article (PubMed ID: 11290608)
1. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Yamamoto Y; Kiyoi H; Nakano Y; Suzuki R; Kodera Y; Miyawaki S; Asou N; Kuriyama K; Yagasaki F; Shimazaki C; Akiyama H; Saito K; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Saito H; Ueda R; Ohno R; Naoe T Blood; 2001 Apr; 97(8):2434-9. PubMed ID: 11290608 [TBL] [Abstract][Full Text] [Related]
2. FLT3-TKD mutation in childhood acute myeloid leukemia. Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Wang LY; Chang WH Leukemia; 2003 May; 17(5):883-6. PubMed ID: 12750701 [TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of FLT3 ITD and D835 mutations in AML patients. Sheikhha MH; Awan A; Tobal K; Liu Yin JA Hematol J; 2003; 4(1):41-6. PubMed ID: 12692519 [TBL] [Abstract][Full Text] [Related]
4. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077 [TBL] [Abstract][Full Text] [Related]
5. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Yokota S; Kiyoi H; Nakao M; Iwai T; Misawa S; Okuda T; Sonoda Y; Abe T; Kahsima K; Matsuo Y; Naoe T Leukemia; 1997 Oct; 11(10):1605-9. PubMed ID: 9324277 [TBL] [Abstract][Full Text] [Related]
6. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Grundler R; Thiede C; Miething C; Steudel C; Peschel C; Duyster J Blood; 2003 Jul; 102(2):646-51. PubMed ID: 12663439 [TBL] [Abstract][Full Text] [Related]
8. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Kiyoi H; Ohno R; Ueda R; Saito H; Naoe T Oncogene; 2002 Apr; 21(16):2555-63. PubMed ID: 11971190 [TBL] [Abstract][Full Text] [Related]
9. FLT3 in human hematologic malignancies. Kiyoi H; Naoe T Leuk Lymphoma; 2002 Aug; 43(8):1541-7. PubMed ID: 12400596 [TBL] [Abstract][Full Text] [Related]
10. Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients. Wang L; Lin D; Zhang X; Chen S; Wang M; Wang J Leuk Res; 2005 Dec; 29(12):1393-8. PubMed ID: 15996732 [TBL] [Abstract][Full Text] [Related]
11. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Mizuki M; Fenski R; Halfter H; Matsumura I; Schmidt R; Müller C; Grüning W; Kratz-Albers K; Serve S; Steur C; Büchner T; Kienast J; Kanakura Y; Berdel WE; Serve H Blood; 2000 Dec; 96(12):3907-14. PubMed ID: 11090077 [TBL] [Abstract][Full Text] [Related]
12. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064 [TBL] [Abstract][Full Text] [Related]
13. Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Clark JJ; Cools J; Curley DP; Yu JC; Lokker NA; Giese NA; Gilliland DG Blood; 2004 Nov; 104(9):2867-72. PubMed ID: 15256420 [TBL] [Abstract][Full Text] [Related]
14. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. Jilani I; Estey E; Manshuri T; Caligiuri M; Keating M; Giles F; Thomas D; Kantarjian H; Albitar M Leukemia; 2003 Jan; 17(1):114-9. PubMed ID: 12529667 [TBL] [Abstract][Full Text] [Related]
15. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Bagrintseva K; Schwab R; Kohl TM; Schnittger S; Eichenlaub S; Ellwart JW; Hiddemann W; Spiekermann K Blood; 2004 Mar; 103(6):2266-75. PubMed ID: 14604974 [TBL] [Abstract][Full Text] [Related]
16. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908 [TBL] [Abstract][Full Text] [Related]
18. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Taketani T; Taki T; Sugita K; Furuichi Y; Ishii E; Hanada R; Tsuchida M; Sugita K; Ida K; Hayashi Y Blood; 2004 Feb; 103(3):1085-8. PubMed ID: 14504097 [TBL] [Abstract][Full Text] [Related]
19. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Kiyoi H; Towatari M; Yokota S; Hamaguchi M; Ohno R; Saito H; Naoe T Leukemia; 1998 Sep; 12(9):1333-7. PubMed ID: 9737679 [TBL] [Abstract][Full Text] [Related]
20. Low frequency of FLT3 gene internal tandem duplication and activating loop mutation in therapy-related acute myelocyticleukemia and myelodysplastic syndrome. Au WY; Fung AT; Ma ES; Liang RH; Kwong YL Cancer Genet Cytogenet; 2004 Mar; 149(2):169-72. PubMed ID: 15036894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]